Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin Alfa

NCT02648126 | Unknown Phase 4

• 1 other identifier: ASCLIN 004/2014
• Study Type: interventional
• Target: 531
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this study is to determine occurrence of pure red cell aplasia in a group of participants with chronic renal insufficiency and with resistance criteria to epoetin alfa treatment.The investigational product is producted by Bio-Manguinhos / Fiocruz (BIO-EPO) and it is provided by the Unified Health System.

Conditions

Red-Cell Aplasia, Pure; Renal Insufficiency, Chronic

Outcome Measures

Primary Outcomes (1)

• Number of Participants With Hyporesponsiveness to EPO related to anti-alfa epoetin antibodies.

  3 years

Secondary Outcomes (4)

• Serum levels of leukocytes and platelets correlated with anti-alfa epoetin antibodies

  3 years

• Anti-alfa epoetin antibodies titers related to Hemoglobin levels

  3 years

• Hemoglobin levels related to alfa epoetin dosage

  3 years

• Percentage anti-alfa epoetin neutralizing antibodies related to Hemoglobin levels

  3 years

Study Arms (1)

Pure red cell aplasia participants

OTHER

Group of participants with pure red cell aplasia and chronic kidney disease, that have resistance criteria to treatment with epoetin alfa produced by Bio-Manguinhos / Fiocruz. The Patients who meet the appropriate criteria in the selection period will be subject to Pure Red Cell Aplasia diagnostic confirmation.

Procedure: Pure Red Cell Aplasia diagnostic confirmation

Interventions

Pure Red Cell Aplasia diagnostic confirmation PROCEDURE

Patients who meet the appropriate criteria in the selection period will be subject to Pure Red Cell Aplasia diagnostic confirmation by collecting 20 mL of blood in dialysis units. The samples will be processed, aliquoted and transported to Bio-Manguinhos, where depart periodically (according to the volume of samples) to the reference laboratory Sce Immunologie et d'Hématologie biologiques Hôpital Saint Antoine, where the dosage of antibody will be held anti epoetin alfa

Pure red cell aplasia participants

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Use of alfa epoetin manufactured by Bio-Manguinhos for at least 8 weeks before the moment of hyporesponsiveness diagnosis;
• Nonuse of alfa epoetin from another manufacturer for at least 24 weeks before hyporesponsiveness diagnosis;
• Presence of the criteria for pure red cell aplasia disease, which is absence of a significant reduction in serum levels of leukocytes and platelets.

You may not qualify if:

• The screened patients who have at least one of the following criteria will be excluded from the study, and it may be replaced by another participant for the research.
• if there is no legal representative, an intellectual disability that restrain the compliance and signature of informed consent,
• no agreement assigning the informed consent;
• It will be excluded from the study if from the moment of hyporesponsiveness diagnosis the participant have: lactation pregnancy, hypersensitivity or intolerance previously known for alfa epoetin or one of its components, intolerance or allergy to parenteral iron, acute hemorrhage, kidney transplantation, hemolysis defined as the presence of anemia associated with high levels of indirect bilirubin and lactate dehydrogenase , percentage of reticulocytes\> 1.5% absolute reticulocyte\> 75,000 / microliter.
• deficiency of folate and / or vitamin B12.
• pancytopenia.
• in use with medications known to cause anemia and / or pure red cell aplasia as: Valproic Acid; Azathioprine; Chloramphenicol; Phenytoin; Isoniazid; Mycophenolate mofetil.
• presence of the following comorbidities: Diabetes mellitus; epilepsy; chronic viral hepatitis; secondary hyperparathyroidism uncontrolled; hypertension systolic; inflammation (acute or chronic); myelofibrosis; myelodysplasia; neoplasm and thalassemias;
• severe disease in the 24 weeks before the hyporesponsiveness diagnosis; including: stroke, septic shock, thromboembolic events; acute myocardial infarction
• lack of information or damage to quality data that avoid disease classification as a case of hyporesponsiveness.
• Immunoglobulin M and Immunoglobulin M serology for Parvovirus B19, Epstein-Barr and Cytomegalovirus.
• serology for HIV in the last 12 months.
• established immunological disease.
• dosage of protein C-reactive titrated .
• presence of antinuclear antibody and rheumatoid factor.

Sponsors & Collaborators

• The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz): lead

MeSH Terms

Conditions

Red-Cell Aplasia, Pure; Renal Insufficiency, Chronic

Condition Hierarchy (Ancestors)

Anemia; Hematologic Diseases; Hemic and Lymphatic Diseases; Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Vivian Rotman, M.D.

  Biomanguinhos

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 5, 2016
• First Posted: January 6, 2016
• Study Start: November 1, 2015
• Primary Completion: July 1, 2017
• Study Completion: December 1, 2017
• Last Updated: January 6, 2016

Record last verified: 2016-01